High dose imatinib (STI571, Gleevec®) provides durable long-term outcomes for patients (Pts) with chronic myeloid leukemia (CML) in accelerated phase (AP) or myeloid blast crisis (BC):: Follow-up of the phase II studies.

被引：0
|
作者：
Talpaz, M
Goldman, JM
Sawyers, CL
Hochhaus, A
Silver, RT
Smith, BD
So, C
Gathmann, I
Druker, BJ
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Novartis Pharmaceut Corp, E Hanover, NJ USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3369
引用
收藏
页码：905A / 906A
页数：2
相关论文
共 50 条
  • [1] Imatinib (Gleevec™, STI571) in patients with chronic myeloid leukemia in myeloid blast crisis (CML-BC):: Up to 36 months follow-up of a phase II study.
    Sawyers, CL
    Hochhaus, A
    Feldman, EJ
    Goldman, JM
    Miller, CB
    Ottmann, OG
    Schiffer, CA
    Talpaz, M
    Guilhot, F
    Deininger, MW
    Fischer, T
    O'Brien, SG
    Stone, RM
    Corneo, G
    Tura, S
    Van Hoomissen, IC
    Gathmann, I
    Druker, BJ
    BLOOD, 2002, 100 (11) : 163A - 164A
  • [2] Imatinib (STI571, Gleevec™) achieves prolonged survival in patients with accelerated phase Ph plus chronic myeloid leukemia (CML-AP):: Up to 36 months follow-up of a phase II study.
    Talpaz, M
    Silver, RT
    Druker, BJ
    Paquette, R
    Goldman, JM
    Gambacorti-Passerini, C
    Guilhot, F
    Schiffer, CA
    Fischer, T
    O'Brien, SG
    Deininger, MW
    Hochhaus, A
    Ottmann, OG
    Gratwohl, A
    Tura, S
    Baccarani, M
    Stone, RM
    Reiffers, J
    Bolton, AE
    Gathmann, I
    BLOOD, 2002, 100 (11) : 163A - 163A
  • [3] Gleevec/Glivec (imatinib mesylate, STI-571) in patients with chronic myeloid leukemia (CML) in myeloid blast crisis: Updated results of a phase II study.
    Sawyers, CL
    Hochhaus, A
    Feldman, E
    Goldman, JM
    Miller, C
    Ottman, OG
    Schiffer, CA
    Talpaz, M
    Guilhot, F
    Niederwieser, D
    Ben-Am, M
    Gathmann, I
    Ford, J
    Druker, BJ
    BLOOD, 2001, 98 (11) : 845A - 845A
  • [4] Treatment of accelerated phase of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML AP) with imatinib mesylate (STI571).
    Kantarjian, HM
    O'Brien, S
    Cortes, J
    Faderl, S
    Giles, F
    Thomas, D
    Garcia-Manero, G
    Albitar, M
    Rios, MB
    Shan, J
    Issa, JP
    Resta, D
    Capdeville, R
    Keating, MJ
    Freireich, EJ
    Talpaz, M
    BLOOD, 2001, 98 (11) : 141A - 141A
  • [5] Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials
    Silver, Richard T.
    Cortes, Jorge
    Waltzman, Roger
    Mone, Manisha
    Kantarjian, Hagop
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (05): : 743 - 744
  • [6] Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy
    Tantiworawit, Adisak
    Power, Maryse M.
    Barnett, Michael J.
    Hogge, Donna E.
    Nantel, Stephen H.
    Nevill, Thomas J.
    Shepherd, John D.
    Song, Kevin W.
    Sutherland, Heather J.
    Toze, Cynthia L.
    Abou-Mourad, Yasser R.
    Narayanan, Sujaatha
    Broady, Raewyn C.
    Forrest, Donna L.
    LEUKEMIA & LYMPHOMA, 2012, 53 (07) : 1321 - 1326
  • [7] Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials.
    Silver, RT
    Talpaz, M
    Sawyers, CL
    Druker, BJ
    Hochhaus, A
    Schiffer, CA
    Guilhot, F
    Goldman, JM
    Smith, BD
    Mone, M
    Kranhnke, T
    Kantarjian, HM
    BLOOD, 2004, 104 (11) : 11A - 11A
  • [8] Imatinib (Gleevec®)) maintains favorable long-term outcomes in chronic-phase chronic myeloid leukemia (CML) for patients failing interferon-alpha (IFN) -: Follow-up of a phase II study.
    Kantarjian, HM
    Schiffer, CA
    Sawyers, CL
    Hochhaus, A
    Guilhot, F
    Niederwieser, DW
    Gambacorti, C
    Stone, RM
    Goldman, JM
    Fischer, T
    Reiffers, J
    O'Brien, S
    Smith, BD
    Tallmann, MS
    Brown, RA
    Silver, RT
    Gratwohl, A
    So, C
    Gathmann, I
    Hensley, ML
    Druker, BJ
    BLOOD, 2003, 102 (11) : 905A - 905A
  • [9] Seven year follow-up of the International Randomized Study of Interferon Versus STI571 (IRIS) demonstrates durable efficacy and long-term safety of imatinib in patients (pts) with newly diagnosed chronic myeloid leukaemia in chronic phase (CML-CP)
    O'Brien, S. G.
    Guilhot, F.
    Goldman, J. M.
    Hochhaus, A.
    Hughes, T. P.
    Radich, J. P.
    Rudoltz, M.
    Filian, J.
    Gathmann, I.
    Druker, B. J.
    Larson, R. A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 : 40 - 41
  • [10] Gleevec™ (formerly STI571):: An active drug in patients with Ph plus chronic myeloid leukemia in accelerated phase -: Updated results of a phase II study.
    Talpaz, M
    Silver, RT
    Druker, B
    Paquette, R
    Goldman, JM
    Gambacorti-Passerini, C
    Guilhot, F
    Schiffer, CA
    Reese, SF
    Kantarjian, HM
    Ford, JM
    BLOOD, 2001, 98 (11) : 845A - 845A
12345